Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
NCT03148275 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is completed. It studies Trametinib in Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma and 1 more condition. The registry lists an enrollment of 44 participants at 36 sites in 1 country. The registry lists a start date of 20 Jun 2017 and a primary completion date of 23 Jun 2023. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03148275 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | National Cancer Institute (NCI) |
| Enrollment | 44 |
| Registered sites | 36 |
| Countries | 1 |
| Conditions | Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma and Unresectable Epithelioid Hemangioendothelioma |
| Drugs | Trametinib |
| Start | 20 Jun 2017 |
| Primary completion | 23 Jun 2023 |
| Study completion | 23 Jun 2023 |
| Last update posted | 26 Nov 2024 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Scott M Schuetze
University of Michigan Comprehensive Cancer Center EDDOP
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Hospital in Arizona
Phoenix
- Mayo Clinic in Arizona
Scottsdale
- Stanford Cancer Institute Palo Alto
Palo Alto
- Uchealth University of Colorado Hospital
Aurora
- Smilow Cancer Center/yale-New Haven Hospital
New Haven
- Yale University
New Haven
- Mayo Clinic in Florida
Jacksonville
- Northwestern University
Chicago
- University of Kansas Clinical Research Center
Fairway
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore
- Beth Israel Deaconess Medical Center
Boston
- Brigham and Women's Hospital
Boston
- Dana-Farber Cancer Institute
Boston
- Massachusetts General Hospital Cancer Center
Boston
- University of Michigan Comprehensive Cancer Center
Ann Arbor
- Mayo Clinic in Rochester
Rochester
- Siteman Cancer Center at West County Hospital
Creve Coeur
- Washington University School of Medicine
St Louis
- Nebraska Medicine-Bellevue
Bellevue
- Nebraska Medicine-Village Pointe
Omaha
- University of Nebraska Medical Center
Omaha
- Roswell Park Cancer Institute
Buffalo
- Memorial Sloan Kettering Cancer Center
New York
- Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York
- Montefiore Medical Center - Moses Campus
The Bronx
- Montefiore Medical Center-Einstein Campus
The Bronx
- Montefiore Medical Center-Weiler Hospital
The Bronx
- Duke University Medical Center
Durham
- Cleveland Clinic Foundation
Cleveland
- Ohio State University Comprehensive Cancer Center
Columbus
- Fox Chase Cancer Center
Philadelphia
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh
- Vanderbilt Breast Center at One Hundred Oaks
Nashville
- Vanderbilt University/ingram Cancer Center
Nashville
- M D Anderson Cancer Center
Houston
- Huntsman Cancer Institute/university of Utah
Salt Lake City
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03148275
Each answer restates registry values shown on this page.
What is NCT03148275?
NCT03148275 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Trametinib in Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma and 1 more condition.
Who leads NCT03148275?
The registry names Scott M Schuetze (principal investigator, University of Michigan Comprehensive Cancer Center EDDOP) as the overall official.
Where does NCT03148275 run?
The registry lists 36 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03148275 study?
The registered drug and biological interventions are Trametinib.
When did NCT03148275 end?
The registry lists a primary completion date of 23 Jun 2023 and a study completion date of 23 Jun 2023. The sponsor last updated the record on 26 Nov 2024.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.